RESEARCH - Hodgkin's lymphoma in SLE

[Guest guest]

Rheumatology Advance Access originally published online on January 25, 2007

Hodgkin's lymphoma in systemic lupus erythematosus

S. Bernatsky1, R. Ramsey-Goldman2, D. Isenberg3, A. Rahman3, M. A. Dooley4,

J. Sibley5, J.-F. Boivin6, L. ph1,6, J. Armitage7, A. Zoma8 and A.

e1,9

1Division of Clinical Epidemiology, Montreal General Hospital, Montreal, QC,

Canada, 2Division of Rheumatology, Northwestern University Feinberg School

of Medicine, Chicago IL, USA, 3Centre for Rheumatology, University College,

London, UK, 4University of North Carolina at Chapel Hill, Chapel Hill, NC,

USA, 5Department of Rheumatology, Royal University Hospital, Saskatoon, SK,

Canada, 6Department of Epidemiology and Biostatistics, McGill University,

Montreal, QC, Canada, 7Oncology/Hematology Section; University of Nebraska

Medical Centre: Omaha, NE, USA, 8Lanarkshire Centre for Rheumatology,

Hairmyres Hospital, Lanarkshire, UK and 9Division of Clinical

Immunology/Allergy, Montreal General Hospital, QC, Canada.

Abstract

Objective. In systemic lupus erythematosus (SLE), there is a well-documented

increased risk of non-Hodgkin's lymphoma (NHL), but little is known about

the risk of Hodgkin's lymphoma (HL). The purpose of our work was to describe

the phenomenon of HL in SLE.

Methods. A multi-site cohort of 9547 SLE subjects was assembled; HL cases

were ascertained through cancer registry linkage, and the standardized

incidence ratio (SIR) for HL was determined. We also performed a literature

search for HL cases in SLE, and compared these with our sample. Finally, we

pooled results from our cohort study with two large population-based cohort

studies providing SIR estimates for HL in SLE.

Results. Five cases of HL occurred in our SLE cohort during the observation

interval, for an SIR of 2.4 (95% CI 0.8, 5.5). The literature review

documented 13 HL case reports developing in patients with SLE. A pooled

analysis combining our data with the other large cohort studies yielded a

standardized incidence ratio of 3.16 (95% CI, 1.63-5.51) for HL in SLE.

Conclusions. Data suggest that risk in SLE is increased not only for NHL,

but also for other malignancies arising from B-lymphocytes, including HL.

http://rheumatology.oxfordjournals.org/cgi/content/abstract/46/5/830?etoc

Not an MD